Scienture Holdings, Inc. SCNX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Scienture Holdings, Inc. (SCNX) is a healthcare company listed in the US with a market value of about $5M. In the twelve months to June 30, 2026 it had revenue of $821315 and net income of -$38M, a net margin of -4620.9%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -52% a year, a 5-year average ROIC of -61%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
About Scienture
Scienture is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2014 to $431609 in 2025, a decline of about 10.7% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 2609% over three years (dilution for shareholders). It spends 453% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $821315 | $431609 | — | $1M | $10M | $10M | $17M | $7M | $4M | $3M | $2M |
| Net income | -$38M | -$42M | $9M | -$18M | -$3M | -$5M | -$3M | -$284428 | $9038 | $288983 | -$3M |
| Free cash flow | — | — | -$14M | — | -$2M | -$3M | -$2M | $59523 | $258380 | — | — |
| EPS (diluted) | $-2.10 | $-2.70 | $2.48 | $-23.35 | $-6.13 | $-0.65 | $-0.33 | $-0.05 | $0.00 | $0.06 | $-0.54 |
| Net margin | -4620.9% | -9618.0% | — | -1308.3% | -33.9% | -53.8% | -14.8% | -3.8% | 0.2% | 9.9% | -111.2% |
| ROIC | — | -57.9% | -17.4% | -45.4% | -98.7% | -83.3% | -21.8% | 1.9% | -5.1% | 88.0% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Scienture stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Scienture pay a dividend?
Not currently.
Is Scienture a good stock to buy?
We do not give buy or sell advice. Scienture scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.